| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
others
α1-3,4,6 Galactosidase targets terminal non-reducing α1-3, α1-4, and α1-6-linked galactose residues in oligosaccharides. It does not have a pharmacological target but is an enzymatic tool used in glycobiology research for glycan analysis and structural studies. |
|---|---|
| ln Vitro |
In vitro, α1-3,4,6 Galactosidase catalyzes the hydrolysis of terminal, non-reducing α1-3, α1-4, and α1-6-linked galactose residues from oligosaccharides. It is used in enzymatic assays to determine glycan structures. It is available as a purified enzyme preparation.
|
| ln Vivo |
In vivo, α1-3,4,6 Galactosidase is not typically used as a therapeutic agent. It is used in research applications for glycan analysis. No pharmacological activities are reported.
|
| Enzyme Assay |
Cell-free enzyme assays for α1-3,4,6 Galactosidase: enzyme activity is measured using p-nitrophenyl-α-D-galactopyranoside or other chromogenic substrates. The enzyme is incubated with substrate in buffer at appropriate pH and temperature. Release of p-nitrophenol is measured at 405 nm. One unit is defined as the amount of enzyme hydrolyzing 1 µmole of substrate per minute.
|
| Cell Assay |
Cellular assays for α1-3,4,6 Galactosidase: cells are not typically treated with this enzyme as it acts on extracellular glycans. The enzyme is used in glycobiology research to analyze cell surface glycans. No direct cellular effects are reported.
|
| Animal Protocol |
In vivo animal studies for α1-3,4,6 Galactosidase: the enzyme is not administered to animals as a therapeutic agent. No specific pharmacological studies are reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of α1-3,4,6 Galactosidase: as an enzyme, it is not intended for systemic administration. No systemic pharmacokinetics are applicable. The enzyme is available as an off-white to light yellow solid powder.
|
| Toxicity/Toxicokinetics |
Toxicity of α1-3,4,6 Galactosidase: as an enzyme, it is generally well-tolerated. In research settings, the enzyme is considered safe for laboratory use. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
α1-3,4,6 Galactosidase is a research enzyme used in glycobiology for glycan analysis and structural studies. It is available as a purified enzyme preparation. Its primary application is in the hydrolysis of terminal galactose residues from oligosaccharides. No clinical applications have been reported.
|
| Exact Mass |
192.009
|
|---|---|
| CAS # |
9025-35-8
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
324.4±22.0 °C at 760 mmHg
|
| Flash Point |
150.0±22.3 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.663
|
| LogP |
2.12
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
